People with HIV who develop certain cancers are more likely to die from them than patients without HIV—even if they receive similar treatment.
by Jon Kelvey
Immune checkpoint inhibitors can be effective treatments for elderly people with some types of advanced cancer, but more information is needed on their risks and benefits in this group.
by Emma Yasinski
Uterine cancer incidence is increasing in the U.S., particularly in Hispanic, Asian and black women, but obesity may play a smaller role in this change than was previously assumed.
by Ashley P. Taylor
For the first time, people living in the Navajo Nation who are diagnosed with cancer can get treated for the disease without leaving tribal lands.
by Kate Yandell
FROM THE EDITOR-IN-CHIEF
DNA sequencing of blood cells may provide clues for how cancer and other illnesses develop.
by William G. Nelson, MD, PhD
Researchers want to find out when cancer patients can benefit from receiving lower doses of drugs or radiation, shortening treatment or skipping certain treatments altogether.
Irene Ghobrial on studying cancer precursors.
by Sue Rochman
At-home genetic tests offer limited information on cancer risk.
by Sharon Tregaskis
Proton therapy, an alternative to standard radiation therapy, is safe and effective. But evidence is lacking that it’s always a better option than standard radiation, and some insurers balk at the higher price tag.
E-cigarettes are upending decades of smoke-free successes.
by Nancy Averett
After her diagnosis with ovarian cancer, Patricia Anne Ward noticed that some friends and family pulled away. She found connection outside her usual circles.
by Patricia Anne Ward
My most meaningful moments at my first cancer research conference came from embracing my experience as a patient—not as a researcher.
by Jamie Aten
Minister and thyroid cancer survivor Thurselle C. Williams speaks at conferences and events about cancer awareness and, ultimately, healing following her 2016 diagnosis.
by Erin L. Boyle
Ovarian cancer is a fairly rare cancer. It is also a deadly cancer, with only 47.6% of patients surviving for five years or longer.
The U.S. Food and Drug Administration has approved a second targeted therapeutic based on tumor biomarker, not tumor origin.
Project GENIE links clinical-grade cancer genomic data with clinical outcomes from tens of thousands of cancer patients.
A Lesson in Service
donate to the AACR